Pan-Canadian Projects
The Marathon of Hope Cancer Centres Network is happy to introduce its Pan-Canadian Projects program, which unites researchers and clinicians from multiple provinces to work on projects that accelerate precision medicine for cancer in Canada.
In total, the Network will fund 20 groups through this initiative, representing a multi-million-dollar investment over the next three years that will contribute roughly 6,000 cases to the MOHCCN Gold Cohort, the largest and most complete cancer case resource in Canada.
“Until now, the bulk of our investment has supported projects within specific geographic regions, helping to create synergies within those regions and establishing the policy and technological framework needed to generate data nationally according to Network standards,” says Dr. André Veillette, executive director of the MOHCCN. “Now that these synergies exist, we are expanding our investment to projects that unite these regions, integrating researchers and clinicians in new and exciting ways.”
“This is where we will see the true impact of the Network on the Canadian cancer research and care landscape, which is why we are extremely excited about this program.”
The 20 groups that will eventually make up the MOHCCN Pan-Canadian Projects were selected after a two-year process that began with a call for White Papers in November 2021. After an administrative review from Network staff, White Paper authors were contacted for their authorization to share their proposals with members of the MOHCCN Scientific Questions Working Group (SQWG) and collaborators.
The SQWG reviewed the White Papers and identified four themes emerging from the proposals that would be the basis for future projects. These themes – (i) mechanisms of drug resistance, (ii) dynamic biomarkers, (iii) prospective treatment assignment based on molecular/immune characterization and (iv) understanding cancer biology of rare and understudied cancer subtypes – along with a review criterion for a Request for Applications, were then endorsed by MOHCCN Network Council, and a request for applications was sent out. Out of the 35 applications received, 20 groups were selected to receive funding after undergoing peer review.
Projects
-
Predicting response to CAR-T cell therapy in lymphoma patientsRead more
-
A pan-Canadian collaboration to address therapy resistance in acute myeloid leukemia (AML) by collecting and analyzing clinical data, whole genome, and transcriptome sequences of AML cells to understa...Read more
-
National precision medicine-based initiative to define genomic drivers of triple negative myeloproliferative neoplasms
Key ResearchersAccelerating precision medicine for patients with myeloproliferative neoplasmsRead more -
Early Cancer Detection and Interception for Molecular Residual Disease (MRD) in Solid Tumours
Key ResearchersFinding the hidden seeds of cancer recurrenceRead more -
Enabling precision oncology in rare types of gynecologic cancer
Key ResearchersStrength in numbers: Pan-Canadian experts team up to turn the tide on rare gynecological cancersRead more -
Marathon of HopE Genome Sequencing to Inform Novel Treatments Portfolio Trial (MAESTRO)
Key ResearchersA clinical trial to personalize cancer therapies for patients with advanced pancreatic cancerRead more -
Integrated genomics and spatial heterogeneity to enhance personalized therapies for rare metaplastic breast carcinomas
Key ResearchersSharing data and expertise to accelerate research into rare and aggressive breast cancersRead more -
High-grade serous ovarian cancer (HGSOC): optimizing long-term outcomes in the PARPi era
Key ResearchersBetter understanding differences in treatment response in patients with high-grade serous ovarian carcinoma treated with PARP inhibitorsRead more -
Neoadjuvant precision therapy for non-small cell lung cancer: A platform for discovery
Tracking immunotherapy response to personalize treatment for lung cancer patientsTracking immunotherapy response to personalize treatment for lung cancer patientsRead more -
Longitudinal Molecular Characterization of Lethal Prostate Cancer: A Major Step Towards Precision Oncology
Key ResearchersA multi-pronged approach to accelerate precision medicine for prostate cancer in CanadaRead more -
The Pan-Canadian Lower-grade Glioma (MOH-PCLG) project: Enabling biomarker-driven treatment options for relapsed IDH-mutant gliomas
Key ResearchersUnravelling the evolutionary biology of IDH-mutant gliomas to improve treatment options for relapsed patientsRead more -
Canadian Head And Neck cancer GEnomic (CHANGE) Collaborative
Understanding the molecular underpinnings of high recurrence rates in oral squamous cell carcinoma to improve survival and quality of life for patientsKey Researchers -
Canadian framework to improve predictive models for immunotherapy interventions (CAN-PREDICT-IT)
Developing multi-modal biomarkers to predict response to specific immunotherapiesKey ResearchersDeveloping multi-modal biomarkers to predict response to specific immunotherapiesRead more -
Identification of biomarkers to guide the duration of immunotherapy treatment for melanoma patients
Key ResearchersInvestigating optimal immunotherapy conditions in metastatic melanoma to improve patient outcomes and experiencesRead more -
Canadian Platform to Investigate Primary and Acquired Resistance to Cancer Immunotherapy (CAN-PIVOT)
Key ResearchersUnderstanding resistance to immunotherapy to improve treatment opportunities and outcomesRead more
Related News
-
PM2 CAN-IMPACT-IO a national immunotherapy biospecimen collection study has now opened
PM2 CAN-IMPACT-IO is a unique national initiative to measure, predict and assess cancer treatment outcomes in patients who have been treated with immunotherapy. Patients on CCTG clinical trials who co... -
New pan-Canadian project aims to discover if personalized lifestyle interventions can help improve the efficacy of prostate cancer treatments
A pan-Canadian team of researchers and clinicians will seek to better understand if lifestyle interventions can help improve the efficacy of prostate cancer treatments thanks to new funding from the M... -
New hope for pancreatic cancer treatments [EXTERNAL MEDIA]
(Globe and Mail, June 21, 2024) Marathon of Hope Cancer Centres Network supports clinical trial to increase personalized treatment based on an individual’s cancer genetics -
Marathon of Hope Cancer Centres Network and Canadian Cancer Trials Group partner on three pan-Canadian projects aimed at making immunotherapy more effective for cancer patients
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand ...